A new study shows that CD8-positive T cells play a significant role in the early stages of multiple sclerosis (MS).
GlobalData on MSN23h
NIH selects Emergex’s T cell vaccine for trials under Project NextGen"NIH selects Emergex’s T cell vaccine for trials under Project NextGen" was originally created and published by Clinical ...
A new poll of voters conducted earlier this week shows a very tight race in Colorado's eighth congressional district between ...
LMU researchers demonstrate that certain immune cells already play an important role in the early stages of multiple sclerosis ...
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer ...
Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune ...
Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of ...
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of synthetic T cell-priming ...
Researchers at the Spanish National Cancer Research Center (CNIO) propose a new treatment for brain metastases that respond ...
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will ...
CD8-positive T cells are a critical subpopulation of MHC class I-restricted T cell and are mediators of adaptive immunity. They include cytotoxic T cells, which are important for killing cancerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback